Arkin Capital announced it has closed Arkin Bio Ventures III, a $100 million fund that will back advanced pre-clinical and early clinical-stage biotechnology companies developing therapies for high unmet medical needs.
The firm said the new vehicle is supported by institutional investors, including Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, as well as a significant commitment from Arkin Capital. Arkin Bio Ventures III plans to invest in 10 to 12 companies globally, with a focus on programs in oncology, immunology, inflammation, rare diseases, and other high-impact therapeutic areas.
Arkin positioned the strategy as combining scientific diligence with hands-on drug development support, working with founders on biological strategy, translational planning, and clinical positioning to help companies reach value inflection points and become attractive to later-stage investors and strategic partners. The firm also emphasized an approach shaped by downstream requirements such as data integrity and the need for clinical proof-of-concept in patients.
Arkin Bio Ventures III is led by Dr. Pini Orbach and commemorates the late Alon Lazarus, whom the firm credited as playing a central role in the fund’s formation. The new fund continues a strategy launched with Arkin Bio Ventures I in 2016 and expanded with Arkin Bio Ventures II in 2020.
With the launch of its third early-stage biotech fund, Arkin Bio said it now manages more than $600 million in biotech-focused assets across early- and late-stage strategies.
Arkin Capital is a multi-asset investment manager with more than $2 billion in assets under management across 12 funds, investing through four primary arms: Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate. The firm said its broader portfolio has generated more than 20 exits across sectors, with a longstanding focus on healthcare and life sciences.
Arkin Bio said it invests globally through early-stage funds under Arkin Bio Ventures and late-stage vehicles under Arkin Bio Capital, citing prior exits via IPOs and acquisitions, including UroGen Pharma, Bluejay Therapeutics, Keros Therapeutics, Censa Pharmaceuticals, ImmPACT Bio, cCAM Biotherapeutics, and Hi-Bio.
KEY QUOTE:
“We launched Arkin Bio Ventures III to deepen our commitment to frontline science and the teams bringing it to life. This fund allows us to lean further into advanced pre-clinical opportunities and help accelerate private companies in order to bring breakthrough technologies to proof-of-concept. With our combined scientific expertise, investment discipline, and global network, we’re proud to be a true partner from day one.”
Dr. Pini Orbach, Managing Partner, Arkin Bio
